62 related articles for article (PubMed ID: 16297672)
1. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?
Guadagnino V; Trotta MP; Carioti J; Caroleo B; Antinori A;
Dig Liver Dis; 2006 Feb; 38(2):119-24. PubMed ID: 16297672
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes.
Guadagnino V; Trotta MP; Montesano F; Babudieri S; Caroleo B; Armignacco O; Carioti J; Maio G; Monarca R; Antinori A;
Addiction; 2007 Mar; 102(3):423-31. PubMed ID: 17298650
[TBL] [Abstract][Full Text] [Related]
3. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
Raison CL; Broadwell SD; Borisov AS; Manatunga AK; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
Brain Behav Immun; 2005 Jan; 19(1):23-7. PubMed ID: 15581735
[TBL] [Abstract][Full Text] [Related]
4. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
Jerkeman A; Norkrans G; Lidman C; Westin J; Lagging M; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
Eur J Gastroenterol Hepatol; 2014 May; 26(5):523-31. PubMed ID: 24637496
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
6. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
[TBL] [Abstract][Full Text] [Related]
9. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
Nguyen OK; Dore GJ; Kaldor JM; Hellard ME;
Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
11. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
12. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
[TBL] [Abstract][Full Text] [Related]
13. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.
Tang KH; Herrmann E; Pachiadakis I; Paulon E; Tatman N; Zeuzem S; Naoumov NV
Aliment Pharmacol Ther; 2008 May; 27(9):810-9. PubMed ID: 18221408
[TBL] [Abstract][Full Text] [Related]
15. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU) : guidelines for clinical practice.
De Bie J; Robaeys G; Buntinx F
Acta Gastroenterol Belg; 2005; 68(1):68-80. PubMed ID: 15832590
[TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.
D'Souza R; Main J; Crossey M; Rosenberg W; Murray-Lyon IM; Hayward C; Foster GR
Aliment Pharmacol Ther; 2005 Jan; 21(1):43-7. PubMed ID: 15644044
[TBL] [Abstract][Full Text] [Related]
20. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
